Mavenclad fda approval date?

When did Mavenclad get FDA approval?

Mavenclad (cladribine) was approved by the U.S. FDA on March 7, 2019 for the treatment of certain relapsing forms of multiple sclerosis. [1]

What does the approval date affect (labeling, market exclusivity, and generics)?

The FDA approval date is often used as a reference point for later timelines tied to market exclusivity and patent/competing product strategy. DrugPatentWatch.com tracks these legal and commercial timelines for marketed drugs, including cladribine (Mavenclad). [2]

Sources:
[1] https://www.drugs.com/history/mavenclad.html
[2] https://www.drugpatentwatch.com/p/mavenclad/